Boston Scientific’s removal of its Infinion CX spinal cord stimulator lead has been classified by the Food and Drug Administration as a Class I recall, the agency’s most serious category, after the company reported 1,081 serious injuries tied to leads that can fracture or generate faulty impedance readings. The action applies only to unused leads still sitting in inventory; it does not require removing leads already implanted in patients.
What a Class I recall signals
The FDA reserves a Class I designation for situations where continued use or distribution of a device could cause serious injury or death, its highest-severity label for a recall. In this case, the agency is not ordering explants of leads already placed in patients; it is directing Boston Scientific to pull unused inventory out of circulation before more of the affected leads reach an operating room. The classification does not, by itself, describe how a device fails; that detail comes from the company’s own report of what triggered the action.
What triggered the recall
Boston Scientific told the FDA that the Infinion CX lead body can experience mechanical stress at the point where it anchors near the spine, which can produce abnormally high impedance measurements or an outright fracture of the lead. Spinal cord stimulator leads carry electrical pulses from an implanted pulse generator, typically placed in the lower abdomen or gluteal region, to the epidural space near the spinal cord, where the pulses are meant to interrupt pain signals before they reach the brain. The devices are used mainly in patients with chronic back or limb pain who have not found relief through surgery or medication, including cases of failed back surgery syndrome and complex regional pain syndrome. When a lead’s impedance drifts out of range or the wire itself breaks, the device can deliver inadequate stimulation, leaving patients without the pain relief the implant was meant to provide.
The scope of the action
The recall, detailed in an FDA notice published September 3, covers two Infinion CX Lead Kit models, a 50-centimetre version and a 70-centimetre version, both compatible with Boston Scientific’s Spectra WaveWriter and WaveWriter Alpha stimulator systems. Boston Scientific sent a letter to affected customers on June 17 instructing them to immediately stop using or distributing the leads, segregate any remaining stock, and return the devices to the company. The FDA notice tells providers to share the communication with any colleagues or facilities that might still have the product on hand. Health care professionals and patients who experience an adverse reaction or a quality problem connected to the device are directed to report it to the FDA’s MedWatch safety information and adverse event reporting program, the same channel that fed the injury count behind this recall.
How the injury count was reached
As of May 27, Boston Scientific had logged 1,081 serious injuries connected to the mechanical stress issue, and no deaths, according to the FDA notice. In a statement reported by MedTech Dive, the company said an event counts as a serious injury under FDA reporting rules whenever medical or surgical intervention is required, and that “the most frequently observed harm is inadequate stimulation.” Boston Scientific said that if reprogramming the device does not resolve a loss of stimulation, patients may need additional surgery to explant and replace the affected lead, which the company describes as the most serious outcome tied to the defect.
Why already-implanted leads are excluded
The recall is explicitly limited to unused Infinion CX leads that remain in distribution or on shelves; the FDA notice states plainly that the action does not affect devices already implanted in patients and that no additional monitoring beyond routine clinical follow-up is recommended for people who already have the lead in place. For patients currently living with an implanted Infinion CX lead, Boston Scientific said any high-impedance or reduced-stimulation problem can typically be evaluated through standard troubleshooting and reprogramming during a normal follow-up visit, and that a failing lead can usually be removed and replaced without disturbing the implanted stimulator itself. That distinction matters because a spinal cord stimulator system is made up of several separate components; a problem confirmed to sit in the lead does not necessarily mean the implanted pulse generator or the rest of the system needs to come out as well.
A recall that overlaps with a planned phase-out
The removal coincides with a transition Boston Scientific had already begun. The company has stopped manufacturing the Infinion CX lead and said the newer Infinion Pro lead has replaced it for new implants and for any lead replacements going forward. That timing does not change the safety basis for the Class I classification, which reflects the FDA’s judgment that continued use of the unused Infinion CX stock could cause serious injury, but it means providers reordering leads for future procedures were already being steered toward the newer model before the recall notice went out. The action is logged in the FDA’s public enforcement database alongside the agency’s broader recall and early alert system, where it will remain searchable alongside the eventual outcome of Boston Scientific’s effort to collect the remaining unused stock.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- A handful of car transmissions are so tough that mechanics say they almost never die
- Card skimmers hidden on gas pumps are draining accounts, and there’s a quick way to spot them
- The NSA warns one messaging setting can clone your texts to a stranger
- Security experts still urge phone owners to switch off one location-tracking setting
